CompletedNCT05193578
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Medication studyAges 18–60DenmarkSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- OdenseSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: January 1, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 154
- Sponsor
- Jan Frystyk
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT05193578
- Official title
Show the full official title
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Recruitment & locations
CompletedOdense
Questions about this study
Who is behind this study?
The study sponsor is Jan Frystyk.
Did this study involve medication?
Yes. The study involved medication, including Semaglutide, 1.34 mg/mL.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni...